Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 14.22 USD 3.04% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Intellia Therapeutics Inc?
Write Note

Wall Street
Price Targets

NTLA Price Targets Summary
Intellia Therapeutics Inc

Wall Street analysts forecast NTLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NTLA is 60.18 USD with a low forecast of 14.14 USD and a high forecast of 134.4 USD.

Lowest
Price Target
14.14 USD
1% Downside
Average
Price Target
60.18 USD
323% Upside
Highest
Price Target
134.4 USD
845% Upside

NTLA Last Price Targets
Intellia Therapeutics Inc

The latest public price target was made on Nov 11, 2024 by Jay Olson from Oppenheimer , who expects NTLA stock to rise by 322% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Jay Olson
Oppenheimer
60 USD
Upside 322%
1 week ago
Nov 11, 2024
Intellia Therapeutics (NTLA) PT Lowered to $60 at Oppenheimer
StreetInsider
Jack Allen
Robert W. Baird
18 USD
Upside 27%
4 weeks ago
Oct 24, 2024
Intellia Therapeutics (NTLA) PT Lowered to $18 at Baird
StreetInsider
Luca Issi
RBC Capital
54 USD
Upside 280%
3 months ago
Aug 9, 2024
Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital
StreetInsider
Dae Gon Ha
Stifel Nicolaus
80 USD
Upside 463%
4 months ago
Jun 24, 2024
Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
StreetInsider
Jack Allen
Robert W. Baird
24 USD
Upside 69%
4 months ago
Jun 24, 2024
Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'
StreetInsider
Kostas Biliouris
BMO Capital
70 USD
Upside 392%
6 months ago
May 10, 2024
Intellia Therapeutics (NTLA) PT Raised to $70 at BMO Capital
StreetInsider
Unknown Analyst
Cantor Fitzgerald
67 USD
Upside 371%
1 year ago
Feb 1, 2023
Cantor Fitzgerald Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $67
Benzinga
Show More Price Targets
Show Less Price Targets
Jay Olson
Oppenheimer
Price Target 60 USD
Upside/Downside 322%
View Source
Jack Allen
Robert W. Baird
Price Target 18 USD
Upside/Downside 27%
View Source
Luca Issi
RBC Capital
Price Target 54 USD
Upside/Downside 280%
View Source
Dae Gon Ha
Stifel Nicolaus
Price Target 80 USD
Upside/Downside 463%
View Source
Jack Allen
Robert W. Baird
Price Target 24 USD
Upside/Downside 69%
View Source
Kostas Biliouris
BMO Capital
Price Target 70 USD
Upside/Downside 392%
View Source
Unknown Analyst
Cantor Fitzgerald
Price Target 67 USD
Upside/Downside 371%
View Source
Show More Price Targets
Show Less Price Targets
Intellia Therapeutics Inc Competitors:
Price Targets
603087
Gan & Lee Pharmaceuticals
55% Upside
ARMP
Armata Pharmaceuticals Inc
217% Upside
DSGN
Design Therapeutics Inc
53% Upside
AVTE
Aerovate Therapeutics Inc
11% Downside
SGMT
Sagimet Biosciences Inc
639% Upside
PROB
Probi AB
39% Downside
KMDA
Kamada Ltd
156% Upside
HALO
Halozyme Therapeutics Inc
30% Upside

Revenue
Forecast

Revenue Estimate
Intellia Therapeutics Inc

For the last 8 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 25%. The projected CAGR for the next 3 years is 36%.

25%
Past Growth
36%
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-49%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NTLA's stock price target?
Price Target
60.18 USD

According to Wall Street analysts, the average 1-year price target for NTLA is 60.18 USD with a low forecast of 14.14 USD and a high forecast of 134.4 USD.

What is Intellia Therapeutics Inc's Revenue forecast?
Projected CAGR
36%

For the last 8 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 25%. The projected CAGR for the next 3 years is 36%.

Back to Top